الفهرس 
GlaucomaOnly 14 pages are availabe for public view
 |  | from | 116 |  |  |
| | | from | 116 | | |
Abstract
Abstract
Aim of the study:Study of the effect of topical antiglaucoma medications with
different preservatives as Purite preservative & Benzalkonium chloride on the
ocular surface and dry eye .
Methodology: This is cross section case-control study in which we tested the
effect of topical antiglaucoma medications with different preservatives. Our study
included 20 controls (group A) & 40 glaucoma patients (group B) divided into 20
patients using Alpha-agonist eyedrops containing Purite as preservative & 20
patients using B-blocker eyedrops containing Benzalkonium Chloride(BAK) as
preservative. The patients were recruited from Outpatient Clinic of Ain Shams
University Hospital and the controls from the patients coming to the outpatient
clinic seeking correction of an error of refraction during the period from May
2016 to December 2016.
Results: Our study showed that ocular surface damage in glaucoma patients is
associated with preserved topical medications. There were statistically significant
differences between the glaucoma-treated patients (used Alpha agonist eyedrops
with Purite preservative and B blocker eyedrops with BAK as preservative) and
control group in the clinical tests used to diagnose Ocular Surface Disease(OSD).
In this study, Tear Break up Time(TBUT) was significantly reduced in glaucoma
patients with topical medications as compared to that in controls.Also the
Schirmer test values were significantly different between glaucoma-treated
patients and untreated controls.
Conclusion: B blocker eyedrops induce more damage on the ocular surface
compared to Alpha agonist eyedrops suggesting that Purite preservatives have
less dryness effect than BAK-chloride preservatives.
Key words:Dry eye-Glaucoma-antiglaucoma medications-ocular surface diseasepreservatives.